Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus TRIMPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus TRIMPEX.
CHLOROMYXIN vs TRIMPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial thymidine synthesis and DNA replication.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
5 mg/kg orally every 6 hours for acute infections; 5 mg/kg orally every 12 hours for chronic urinary tract infections.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
8-11 hours; prolonged in renal impairment (creatinine clearance <10 mL/min: 20-40 hours)
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 40-70% as unchanged drug; biliary/fecal: minimal (10-15% as metabolites)
Category C
Category C
Antibiotic
Antibiotic